Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA
Conclusions
Most MESA participants qualified for trial-based primary prevention with statins. Among the individuals for whom trial-based evidence supports efficacy of statin therapy, CAC = 0 and CAC >100 were common and associated with low and high cardiovascular risks, respectively. This information may guide shared decision making aimed at targeting evidence-based statins to those who are likely to benefit the most.
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - Category: Radiology Authors: Mortensen, M. B., Falk, E., Li, D., Nasir, K., Blaha, M. J., Sandfort, V., Rodriguez, C. J., Ouyang, P., Budoff, M. Tags: Original Research Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Cholesterol | Coronary Heart Disease | Heart | Heart Disease | Radiology | Statin Therapy | Study | Women